144 related articles for article (PubMed ID: 36869329)
21. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
Si J; Ma Y; Bi JW; Xiong Y; Lv C; Li S; Wu N; Yang Y
J Exp Clin Cancer Res; 2019 Dec; 38(1):481. PubMed ID: 31801598
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of RCC2 Enhances Cell Motility and Promotes Tumor Metastasis in Lung Adenocarcinoma by Inducing Epithelial-Mesenchymal Transition.
Pang B; Wu N; Guan R; Pang L; Li X; Li S; Tang L; Guo Y; Chen J; Sun D; Sun H; Dai J; Bai J; Ji G; Liu P; Liu A; Wang Q; Xiao S; Fu S; Jin Y
Clin Cancer Res; 2017 Sep; 23(18):5598-5610. PubMed ID: 28606921
[No Abstract] [Full Text] [Related]
23. PAR2 promotes tumor-associated angiogenesis in lung adenocarcinoma through activating EGFR pathway.
Li Y; Huang H; Chen X; Yu N; Ye X; Chen L; Huang Z
Tissue Cell; 2022 Dec; 79():101918. PubMed ID: 36148733
[TBL] [Abstract][Full Text] [Related]
24. Circular RNA CDR1-AS contributes to pemetrexed and cisplatin chemoresistance through EGFR/PI3K signaling pathway in lung adenocarcinoma.
Mao Y; Xu R
Biomed Pharmacother; 2020 Mar; 123():109771. PubMed ID: 31881486
[TBL] [Abstract][Full Text] [Related]
25. AC099850.3/NCAPG Axis Predicts Poor Prognosis and is Associated with Resistance to EGFR Tyrosine-Kinase Inhibitors in Lung Adenocarcinoma.
Bao J; Wu Y; Zhang K; Qi H
Int J Gen Med; 2022; 15():6917-6930. PubMed ID: 36061963
[TBL] [Abstract][Full Text] [Related]
26. Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with
Han X; Luo R; Wang L; Zhang L; Wang T; Zhao Y; Xiao S; Qiao N; Xu C; Ding L; Zhang Z; Shi Y
Am J Cancer Res; 2020; 10(12):4266-4286. PubMed ID: 33414999
[TBL] [Abstract][Full Text] [Related]
27. Junctional adhesion molecule-like protein promotes tumor progression via the Wnt/β-catenin signaling pathway in lung adenocarcinoma.
Wu Q; Li R; Wang QX; Zhang MY; Liu TT; Qu YQ
J Transl Med; 2022 Jun; 20(1):260. PubMed ID: 35672776
[TBL] [Abstract][Full Text] [Related]
28. The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in
Wang Z; Zhang L; Xu W; Li J; Liu Y; Zeng X; Zhong M; Zhu Y
J Inflamm Res; 2022; 15():649-667. PubMed ID: 35140497
[TBL] [Abstract][Full Text] [Related]
29. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
30. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
32. Serum α-1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma.
Xu YF; Xu Y; Li X; Yang XM
Comb Chem High Throughput Screen; 2018; 21(10):755-759. PubMed ID: 30663564
[TBL] [Abstract][Full Text] [Related]
33. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of PELP1 in Lung Adenocarcinoma Promoted E
Zhang D; Dai J; Pan Y; Wang X; Qiao J; Sasano H; Zhao B; McNamara KM; Guan X; Liu L; Zhang Y; Chan MSM; Cao S; Liu M; Song S; Wang L
Pathol Oncol Res; 2021; 27():582443. PubMed ID: 34257530
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.
Wang YJ; Wang QW; Yu DH; Song CK; Guo ZX; Liu XP; Chen C; Yao J; Wang AF; Hu WD
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3245-3254. PubMed ID: 34255150
[TBL] [Abstract][Full Text] [Related]
36. LncRNA PCBP1-AS1 correlated with the functional states of cancer cells and inhibited lung adenocarcinoma metastasis by suppressing the EMT progression.
Li Z; Pan C; Wang Z; Deng X; Zhu Q; Wu W; Chen L
Carcinogenesis; 2021 Jul; 42(7):931-939. PubMed ID: 34107009
[TBL] [Abstract][Full Text] [Related]
37. Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma.
Song H; Liu D; Wang L; Liu K; Chen C; Wang L; Ren Y; Ju B; Zhong F; Jiang X; Wang G; Chen ZS; Zou C
Mol Cancer; 2022 Feb; 21(1):43. PubMed ID: 35144642
[TBL] [Abstract][Full Text] [Related]
38. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K/AKT/NF-κB pathway.
Zhang J; Wang J; Yue K; Li P; Shen W; Qiao X; Wang Y; Wu X
BMC Pulm Med; 2023 Jan; 23(1):32. PubMed ID: 36690987
[TBL] [Abstract][Full Text] [Related]
39. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
[TBL] [Abstract][Full Text] [Related]
40. RHOV promotes lung adenocarcinoma cell growth and metastasis through JNK/c-Jun pathway.
Zhang D; Jiang Q; Ge X; Shi Y; Ye T; Mi Y; Xie T; Li Q; Ye Q
Int J Biol Sci; 2021; 17(10):2622-2632. PubMed ID: 34326698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
